Research programme: ras protein inhibitors - Concordia Pharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator Concordia Pharmaceuticals
- Mechanism of Action Ras protein inhibitors; Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioma in USA (PO)
- 31 Aug 2007 Preclinical trials in Glioma in USA (PO)